浦东创投助力上海科研成果转化

Group 1 - Pudong Venture Capital Group participated in an investment of over 200 million yuan in Shanghai Baiquan Biotechnology Co., Ltd. for its Series A financing [1] - The funds raised will be used to accelerate the registration and clinical development of the first original target CD3L1 anti-tumor drug [1] - Pudong Venture Capital stated that this investment is a proactive layout for original innovative targets and aims to promote the clinical transformation of university research results in Pudong [1]